SWAV vs. PODD, SOLV, TFX, PEN, INSP, GMED, BAX, GKOS, HAE, and MMSI
Should you be buying Shockwave Medical stock or one of its competitors? The main competitors of Shockwave Medical include Insulet (PODD), Solventum (SOLV), Teleflex (TFX), Penumbra (PEN), Inspire Medical Systems (INSP), Globus Medical (GMED), Baxter International (BAX), Glaukos (GKOS), Haemonetics (HAE), and Merit Medical Systems (MMSI). These companies are all part of the "surgical & medical instruments" industry.
Insulet (NASDAQ:PODD) and Shockwave Medical (NASDAQ:SWAV) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.
Insulet has higher revenue and earnings than Shockwave Medical. Insulet is trading at a lower price-to-earnings ratio than Shockwave Medical, indicating that it is currently the more affordable of the two stocks.
Insulet received 575 more outperform votes than Shockwave Medical when rated by MarketBeat users. Likewise, 66.01% of users gave Insulet an outperform vote while only 55.83% of users gave Shockwave Medical an outperform vote.
In the previous week, Insulet had 4 more articles in the media than Shockwave Medical. MarketBeat recorded 11 mentions for Insulet and 7 mentions for Shockwave Medical. Shockwave Medical's average media sentiment score of 0.98 beat Insulet's score of 0.86 indicating that Insulet is being referred to more favorably in the media.
Shockwave Medical has a net margin of 20.17% compared to Shockwave Medical's net margin of 12.16%. Shockwave Medical's return on equity of 32.19% beat Insulet's return on equity.
Insulet currently has a consensus target price of $240.33, suggesting a potential upside of 30.42%. Shockwave Medical has a consensus target price of $309.11, suggesting a potential downside of 6.47%. Given Shockwave Medical's stronger consensus rating and higher possible upside, equities analysts clearly believe Insulet is more favorable than Shockwave Medical.
95.4% of Shockwave Medical shares are owned by institutional investors. 0.5% of Insulet shares are owned by insiders. Comparatively, 3.4% of Shockwave Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Insulet has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Shockwave Medical has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500.
Summary
Insulet beats Shockwave Medical on 11 of the 18 factors compared between the two stocks.
Get Shockwave Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for SWAV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SWAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Shockwave Medical Competitors List
Related Companies and Tools
